- Neuroscience
- Trials in setup
REVIVE Trial
Testing a gene therapy for an inherited form of vision loss, called Leber Hereditary Optic Neuropathy (LHON)
Research summary
Leber Hereditary Optic Neuropathy (LHON) is a rare, inherited form of vision loss. Treatment options for vision loss from LHON remain limited and no therapies aimed at reversal of the defect are available.
The REVIVE trial aims to assess a gene therapy, called GS010, which has been developed for the early treatment of vision loss in LHON. The effects of GS010 for people with established vision loss is currently unknown. We will be testing GS010 in people with vision loss due to LHON, where both eyes have been affected for more than one and a half years and up to five years.
20 participants will be recruited and half will receive a bilateral injection of GS010, and the other half will undergo a sham procedure. Participants will be followed up for 18 months after the injection procedure.
